PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Certolizumab pegol - Rheumatoid arthritis
PAD Profile : Certolizumab pegol - Rheumatoid arthritis Important
Keywords :
RA, Biologic, NICE, immunosuppressant, Cytokine modulator, TNF Alpha Inhibitor, DMARD, bDmard, Disease modulating, Rheumatology
Brand Names Include :
Cimzia
Important Information :
Severe disease only
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Abatacept
- Etanercept
- Golimumab
- Penicillamine
- Rituximab
- Tocilizumab
- Adalimumab
- Sodium aurothiomalate
- Infliximab
- Baricitinib
- Tofacitinib
- Sarilumab
- Filgotinib
- Upadacitinib
Other Indications
- Any paediatric use
- Psoriatic arthritis
- Ankylosing spondylitis
- Non-radiographic axial spondyloarthritis
- Psoriasis
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
Committee Recommendations
Date
Committee Name
Narrative
03 April 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).
02 December 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Rheumatoid Arthritis High Cost DMARDs Drug Treatment Pathway.
The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs